论文部分内容阅读
多年来人们一直想用处于生长期的结核分枝杆菌(结核杆菌)释放到胞外的蛋白来发展一种预防结核的亚单位疫苗。普遍认为这些蛋白与牛型结核杆菌BCG活菌苗的高效能有关,对这些蛋白的识别,有助于对被感染的巨噬细胞的早期免疫学检测和疾病的控制。结核杆菌的短期培养滤液(ST-CF)中含有丰富的蛋白组分,是新疫苗和诊断试剂候选抗原的主要来源,但到目前为止,约有15个培养滤液蛋白(CFPs)被纯化出来,其中仅有少数几个蛋白如Ag85、ESAT-6可作为新菌苗的候选抗原。此外,还有一些不同Mr的未定性抗原有待进一步筛选和检定。本文主要对从ST-CF中纯化的新而具有免疫活性
For years, people have been trying to develop a subunit vaccine against tuberculosis using M. tuberculosis (Mycobacterium tuberculosis) in its growing phase to release extracellular proteins. It is generally accepted that these proteins are associated with the high potency of B. bovine BCG viable vaccines. The identification of these proteins contributes to early immunological detection and disease control of infected macrophages. Mycobacterium tuberculosis short-term culture filtrate (ST-CF) is rich in protein components and is a major source of candidate antigens for new vaccines and diagnostic reagents. To date, however, about 15 culture filtrate proteins (CFPs) have been purified, Among them, only a few proteins such as Ag85 and ESAT-6 are candidate antigens for new vaccine. In addition, there are some different uncertain antigen Mr needs to be further screening and verification. This article is primarily new and immunologically purified from ST-CF